Product Highlight - DUPIXENT

First and Only Biologic Therapy that specifically targets IL-4 and IL-13, key drivers of persistent underlying Type 2 inflammation (including Atopic Dermatitis, Asthma and CRSwNP)^1,2
Now locally approved for:
- Moderate-to-severe AD in adults and adolescents ≥12 years who are candidates for systemic therapy; severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy¹
- In adults and adolescents ≥12 years as add-on maintenance treatment for severe asthma with type 2 inflammation¹
- As an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control¹

References:
1. DUPIXENT Summary of Product Characteristic. 2022.
2. Gandhi NA et al. Nature Rev Drug Disc 2016; 15: 35–50.

MAT-HK-2200894-1.0-09/2022